Roche human epithelial factor receptor second protein gene two-color in situ hybrid nucleic acid probe combination
Taiwan·Risk Class 3·ROCHE DIAGNOSTICS GMBH;; VENTANA MEDICAL SYSTEMS, INC.·Registered Dec 26, 2011 – Dec 26, 2021Cancelled- Analysis ID
- 8ad0960f609ff229ae2709a801b16dcb
- Customs Code
- DHA00602311902
- Manufacturer Country
- United States;;Germany
- Authorized Representative
- ROCHE DIAGNOSTICS LTD.
- Intended Use
- The purpose of the Roche Human Epithelial Factor Receptor Second Protein Gene Two-color in Situ Hybrid Nucleic Acid Probe Combination is to quantify the amplification of human epithelial factor second protein (HER2) gene directly under light microscopy by formalin fixation and paraffin-embedded human breast cancer and gastric cancer tissue samples, including the gastroesophageal junction, with Roche Vantana automatic multifunctional histopathological staining system, using two-color in situ hybrid staining technology.
- Product Type (Level 1)
- B Hematology, pathology, and genetics
- Product Type (Level 2)
- B.1860 Immunopathological histochemistry reagents and kits
- Import Information
- Contract manufacturing;; input
- Registration Date
- Dec 26, 2011
- Expiry Date
- Dec 26, 2021
- Cancellation Date
- Sep 08, 2023
- Status
- Logged out
- Reason
- 未展延而逾期者
Access comprehensive regulatory information for Roche human epithelial factor receptor second protein gene two-color in situ hybrid nucleic acid probe combination in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 3 medical device is registered under number 8ad0960f609ff229ae2709a801b16dcb and manufactured by ROCHE DIAGNOSTICS GMBH;; VENTANA MEDICAL SYSTEMS, INC.. The authorized representative in Taiwan is ROCHE DIAGNOSTICS LTD..
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.